Diphtheria Toxin
-
Subject Areas on Research
- A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer.
- Astrocytes follow ganglion cell axons to establish an angiogenic template during retinal development.
- Complete and N-terminal amino-acid sequences of CNBr-peptides CB5 and CB3 from diphteria toxin fragment B [proceedings].
- Culture-negative prosthetic valve endocarditis with concomitant septicemia due to a nontoxigenic Corynebacterium diphtheriae biotype gravis isolate in a patient with multiple risk factors.
- Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome.
- Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.
- Depletion of human regulatory T cells.
- Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma.
- Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At.
- Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
- Immune status assay (ISA): a noninvasive procedure for studying allograft rejection.
- Immunotoxin FN18-CRM9 induces stronger T cell signaling than unconjugated monoclonal antibody FN18.
- Immunotoxin-treated rhesus monkeys: a model for renal allograft chronic rejection.
- Impaired fear response in mice lacking GIT1.
- Involvement of protein tyrosine phosphorylation in immunotoxin effects on T lymphocytes.
- Large-scale death of retinal astrocytes during normal development is non-apoptotic and implemented by microglia.
- Mechanisms of tolerance induced by an immunotoxin against CD3 epsilon in a rhesus kidney allograft model.
- Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
- Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma.
- Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
- Reversal of acute allograft rejection using immunotoxin.
- Split tolerance induced by immunotoxin in a rhesus kidney allograft model.
- Treatment with immunotoxin.